As a result of, in accordance with previously announced information, the exercise of 450,494,390 warrants of series TO14 B for subscription of the same number of new Class B shares, as well as the directed issue of 700,238,622 Class B shares, the number of shares and votes in Episurf Medical AB (publ) ("Episurf") has changed.

Through the above-mentioned changes, the total number of shares in Episurf amounts to 2,810,494,390, of which 473,357 are Class A shares and 2,810,021,033 are Class B shares, and the total number of votes in Episurf amounts to 2,811,441,104.

For further information, please contact:

Jens Andersson, CEO, Episurf Medical
Tel: +46(0) 768 55 67 02
Email jens.andersson@episurf.com

This information is information that Episurf Medical AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication, through the agency of the contact person set out above, at 11.45 CET on 27 February 2026.

About Episurf

Episurf Medical is a newly created real estate company with exposure to a diversified portfolio of real estate assets. The Company aims to deliver expansive value creation through Nordic high-yielding properties. The Company also has a medical technology business which is based on the individualised implant Episealer® and related surgical instruments, which are used for treating cartilage damage in joints. Episurf Medical's head office is in Stockholm, Sweden. Its share (EPIS B) is listed on Nasdaq Stockholm. For more information, visit the company's website: www.episurf.com.